(Q44138330)

English

Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.

scientific article published on 25 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

Adam K Wheatley

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Stephen J. Kent

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Carly Siebentritt

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

object named as

Rob J Center

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Shahan M Campbell

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Adriana J Gaeguta

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Viv Peut

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sheilajen Alcantara

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Damian F J Purcell

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

0 references

publication date

25 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

47

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

6605-6612

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19712773%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Combination DNA plus protein HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Combination of HIV‐1–Specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long‐Term Nonprogression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.016

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44138330&oldid=2107014373"